Pramiracetam
| Pramiracetam | |
|---|---|
| Salts [] | |
|---|---|
| Pramiracetam hydrochloride | |
| Pramiracetam sulfate | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 269.38 g/mol [1] |
| Predicted LogP | 0.8 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C14H27N3O2 |
| IUPAC name | N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide |
| SMILES | CC(C)N(CCNC(=O)CN1CCCC1=O)C(C)C |
| InChI | InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18) |
| InChIKey | ZULJGOSFKWFVRX-UHFFFAOYSA-N |
| CAS number | 68497-62-1 |
| UNII | 4449F8I3LE |
| PubChem CID | 51712 |
| Pharmacokinetics[] | |
|---|---|
| Routes of administration | Oral |
Pramiracetam (also known as Pramiracetamum, N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-1-pyrrolidineacetamide, Ci-879 free base, 1-Pyrrolidineacetamide, N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-, 1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-oxo-, N-(2-(bis(1-methylethyl)amino)ethyl)-2-oxo-1-pyrrolidineacetamide, N-{2-[bis(propan-2-yl)amino]ethyl}-2-(2-oxopyrrolidin-1-yl)acetamide, N-(2-(bis(propan-2-yl)amino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide, N06bx16 or N-(2-(diisopropylamino)ethyl)-2-(2-oxopyrrolidin-1-yl)acetamide) is a substance of the racetam class.
Chemistry
Salts []
Pramiracetam is typically found in the form of its hydrochloride and sulfate salts.
Stereochemistry []
Pramiracetam is achiral.
Druglikeness
Lipinski's rule of five
Pramiracetam matches Lipinski's rule of five.Reagents
There are currently 6 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | no color change | |
| Mecke | no color change | |
| Mandelin | no color change | |
| Simon's | no blue color change | |
| Ehrlich | no color change | |
| Hofmann | no color change |
Pharmacology
ATC Classification
- nervous system (N)
- psychoanaleptics (N06)
- psychostimulants, agents used for adhd and nootropics (N06B)
- other psychostimulants and nootropics (N06BX)
- pramiracetam (N06BX16)
Experience reports
Legal status []
- Australia: Pramiracetam is a Schedule 4.
- United States: Pramiracetam is Not FDA approved.
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 51712, Pramiracetam. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/51712
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Pramiracetam. UNII: 4449F8I3LE. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/4449F8I3LE
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 08:01:22 |
| drugspro | ok | 2026-11-20 08:01:18 |
| erowid | ok | 2026-11-20 08:01:19 |
| gsrs | ok | 2026-11-20 08:01:20 |
| hmdb | missing (no HMDB id) | 2026-11-20 08:01:18 |
| kegg | ok | 2026-11-20 08:01:20 |
| pubchem | ok | 2026-11-20 08:01:18 |
| missing (no r/tripreports posts mention it) | 2026-11-20 08:01:18 | |
| sider | missing (not in SIDER) | 2026-11-20 08:01:18 |
| structure | ok | 2026-11-20 08:01:18 |
| wikipedia | ok | 2026-11-20 08:01:18 |